Send me a link:

*Only U.S. numbers are accepted. Text messaging rates may apply.

 Dow Up0.09% Nasdaq Down0.08%

Amyris, Inc. (AMRS)

3.31 Up 0.01(0.30%) 10:50AM EDT - Nasdaq Real Time Price
Get the big picture on all your investments.
ProfileGet Profile for:
Amyris, Inc.
5885 Hollis Street
Suite 100
Emeryville, CA 94608
United States - Map
Phone: 510-450-0761
Fax: 510-225-2645

Index Membership:N/A
Sector:Basic Materials
Industry:Specialty Chemicals
Full Time Employees:392

Business Summary 

Amyris, Inc., a renewable products company, provides various alternatives to a range of petroleum-sourced products for the specialty chemical and transportation fuel markets worldwide. It builds and applies its industrial synthetic biology platform to design microbes, primarily yeast, to convert plant-sourced sugars into renewable hydrocarbons. The company produces and sells Biofene that converts to squalane, which is used as an emollient in cosmetics and other personal care products. It also provides Biofene for specialty chemical applications and transportation fuels, such as diesel. In addition, the company is involved in the development, production, and commercialization of renewable base oils, as well as additives and lubricants for the automotive, industrial, and commercial lubricants markets; and offers natural oils and aroma chemicals for the flavors and fragrances market. It has a strategic partnership with Total for the production and commercialization of diesel and jet fuels. The company was formerly known as Amyris Biotechnologies, Inc. and changed its name to Amyris, Inc. in June 2010. Amyris, Inc. was founded in 2003 and is headquartered in Emeryville, California.

Key Statistics

Company Websites 
Home Page
Search Yahoo! for:
More on Amyris, Inc.

Corporate Governance 
Amyris, Inc.’s ISS Governance QuickScore as of Apr 1, 2014 is 10. The pillar scores are Audit: 5; Board: 7; Shareholder Rights: 8; Compensation: 10.
Brought to you by Institutional Shareholder Services (ISS)

Key Executives 
Mr. John G. Melo , 48
Chief Exec. Officer, Pres and Director
Mr. Paulo Diniz , 57
Interim Chief Financial Officer
Dr. Joel Cherry Ph.D., 53
Pres of R&D
Dr. Kinkead Kinkead Reiling Ph.D., 40
Dr. Jack D. Newman Ph.D., 47
Founder and Chief Science Officer
Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in USD.
View Insiders